Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

7
results for

"Seok Hyun Kim"

Article category

Keywords

Publication year

"Seok Hyun Kim"

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study
Suk-Yong Jang, Woo Sun Rou, Seok Hyun Kim, Byung Seok Lee, Hyuk Soo Eun
Clin Mol Hepatol 2021;27(2):283-294.
Published online December 3, 2020
DOI: https://doi.org/10.3350/cmh.2020.0227
Background/Aims
Current evidence suggests that liver cirrhosis (LC) causes severe psychological stress and depression, which are risk factors for suicide. Although previous studies reported the association between LC and suicidal thoughts, little is known of its effect on suicidal deaths. Therefore, this study was undertaken to investigate the effect of new-onset LC on suicide.
Methods
From the National Health Insurance Service-National Sample Cohort of South Korea, 5,809 incident LC patients and 11,618 risk-set controls matched by propensity score were selected for follow-up. The incidence rate of suicide was estimated using a generalized estimating equation with a Poisson distribution. Effect size was presented as a hazard ratio (HR) using Cox’s proportional hazards model.
Results
The incidence rate of suicide was 143.3 cases per 100,000 person years (95% confidence interval [CI], 100.2–205.1) among the LC cohort. The LC patients were 2.37 times more likely to commit suicide compared with matched controls (HR, 2.37; 95% CI, 1.44–3.88). Increased suicide risk was evident within the first 2 years of the follow-up period (HR, 2.59; 95% CI, 1.20–5.60) and among the 18–49-year-old age group (HR, 3.72; 95% CI, 1.45–9.56).
Conclusions
Our study found increased risk of suicide in patients with new onset LC, especially during the early period following diagnosis and in younger patients. To decrease this suicide risk, a regular and continuous social support system is required.

Citations

Citations to this article as recorded by  Crossref logo
  • Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort
    Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim
    JHEP Reports.2025; 7(2): 101268.     CrossRef
  • Depression and anxiety management in cirrhosis
    Paula C. Zimbrean, Simona S. Jakab
    Hepatology Communications.2025;[Epub]     CrossRef
  • Association Between Triglyceride/High-Density Lipoprotein Ratio and Incidence Risk of Heart Failure: A Population-Based Cohort Study
    Yoon-Kyung Chang, Ju-Young Park, Tae-Jin Song
    Journal of Clinical Medicine.2025; 14(3): 950.     CrossRef
  • Low-density lipoprotein cholesterol and clinical outcomes in patients with liver cirrhosis: a nationwide cohort study
    Byung Sik Kim, Jiyeong Kim, Nayeon Choi, Hyun-Jin Kim, Jeong-Hun Shin
    Annals of Medicine.2025;[Epub]     CrossRef
  • Suicide mortality trends among cancer patients in Taiwan: suicide prevention efforts and cancer care improvements
    Bo-Yu Hsiao, Chun-Ju Chiang, Ya-Wen Yang, Wen-Chung Lee
    American Journal of Epidemiology.2025;[Epub]     CrossRef
  • Understanding the Role of Palliative Care Within Routine Care of Advanced Liver Disease
    Simone A. Jarrett, Edward Bley, Richard S. Kalman
    Current Hepatology Reports.2024; 23(3): 307.     CrossRef
  • Comparative Interrupted Time Series Analysis of Direct Medical Expense and Length of Stay in Elderly Patients with Femoral Neck Fractures Who Underwent Total Hip Arthroplasty and Hemiarthroplasty: A Real World Nationwide Database Study
    Seung-Hoon Kim, Suk-Yong Jang, Yonghan Cha, Bo-Yeon Kim, Hyo-Jung Lee, Gui-Ok Kim
    Clinics in Orthopedic Surgery.2024; 16(2): 217.     CrossRef
  • Stigmatization of drinking patients with liver cancer: The role of socioeconomic status
    Camille Auriol, Patrick Raynal, Nicole Cantisano
    Heliyon.2024; 10(7): e29105.     CrossRef
  • Comparative Interrupted Time Series Analysis of Medical Expenses in Patients with Intertrochanteric Fracture Who Underwent Internal Fixation and Hemiarthroplasty
    Seung-Hoon Kim, Yonghan Cha, Suk-Yong Jang, Bo-Yeon Kim, Hyo-Jung Lee, Gui-Ok Kim
    Hip & Pelvis.2024; 36(2): 144.     CrossRef
  • Impact of long-term care insurance on medical costs and utilization by patients with Parkinson's disease
    Seung Hoon Kim, Eun-Cheol Park, Suk-Yong Jang
    Social Science & Medicine.2023; 317: 115563.     CrossRef
  • Risk of injuries before and after a diagnosis of cirrhosis: A population-based cohort study
    Ying Shang, Qing Shen, Elliot B. Tapper, Axel Wester, Hannes Hagström
    Hepatology Communications.2023;[Epub]     CrossRef
  • Development of Open-Angle Glaucoma in Adults With Seropositive Rheumatoid Arthritis in Korea
    Seung Hoon Kim, Sung Hoon Jeong, Hyunkyu Kim, Eun-Cheol Park, Suk-Yong Jang
    JAMA Network Open.2022; 5(3): e223345.     CrossRef
  • AASLD Practice Guidance: Palliative care and symptom‐based management in decompensated cirrhosis
    Shari S. Rogal, Lissi Hansen, Arpan Patel, Nneka N. Ufere, Manisha Verma, Christopher D. Woodrell, Fasiha Kanwal
    Hepatology.2022; 76(3): 819.     CrossRef
  • Association between new-onset Parkinson’s disease and suicide risk in South Korea: a nationwide cohort study
    Sung Hoon Jeong, Seung Hoon Kim, Doo Woong Lee, Eun-Cheol Park, Suk-Yong Jang
    BMC Psychiatry.2022;[Epub]     CrossRef
  • A need for patient-centered care in managing patients with liver cirrhosis
    Eileen L. Yoon
    Clinical and Molecular Hepatology.2021; 27(2): 270.     CrossRef
  • 9,545 View
  • 213 Download
  • 15 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Young Min Kim, Suk Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae, Myeong Jun Song, Ji Woong Jang, Soon Young Ko, Jae Dong Lee
Clin Mol Hepatol 2018;24(3):311-318.
Published online June 4, 2018
DOI: https://doi.org/10.3350/cmh.2017.0070
Background/Aims
Sofosbuvir plus ribavirin is a standard treatment for patients infected with chronic hepatitis C virus (HCV) genotype 2 in Korea. The purpose of this study was to examine the efficacy and safety of this treatment in Korean patients with chronic HCV genotype 2 infection.
Methods
We retrospectively analyzed clinical data of patients treated with sofosbuvir plus ribavirin for chronic HCV genotype 2 from May 2016 to December 2017 at eight hospitals located in the Daejeon-Chungcheong area.
Results
A total of 172 patients were treated with sofosbuvir plus ribavirin. Of them, 163 patients completed the treatment, and 162 patients were tested for sustained virologic response 12 weeks after treatment discontinuation (SVR12). Mean age was 59.6±12.3 years (27–96), and 105 (64.4%) patients were female. Of the total patients, 49 (30.1%) were diagnosed with cirrhosis, and 31 of them were treated for 16 weeks. Sofosbuvir plus ribavirin was the first-line treatment for 144 (88.3%) patients. Eleven (6.7%) patients were intolerant to previous interferon-based treatment. Eight (5.0%) patients relapsed after interferon-based treatment. HCV RNA non-detection rate at 4, 8, and 12 weeks was 97.5%, 99.1%, and 99.3%, respectively, and SVR12 was 98.8% (161/163). During treatment, 18 (11.0%) patients had to reduce their administrated dose of ribavirin because of anemia. One patient stopped the treatment because of severe anemia. Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16.0%) patients.
Conclusions
A 12-16 week treatment with sofosbuvir plus ribavirin is remarkably effective and well tolerated in Korean patients with chronic HCV genotype 2 infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study
    Ik Sung Choi, Kwang Min Kim, Sang Goon Shim
    Arab Journal of Gastroenterology.2021; 22(1): 23.     CrossRef
  • Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
    Young Joo Park, Hyun Young Woo, Jeong Heo, Sang Gyu Park, Young Mi Hong, Ki Tae Yoon, Dong Uk Kim, Gwang Ha Kim, Hyung Hoi Kim, Geun Am Song, Mong Cho
    Gut and Liver.2021; 15(3): 440.     CrossRef
  • Sofosbuvir‐based therapies in genotype 2 hepatitis C virus cirrhosis: A real‐life experience with focus on ribavirin dose
    Carlo Smirne, Antonio D'Avolio, Mattia Bellan, Alessandro Gualerzi, Maria G. Crobu, Mario Pirisi
    Pharmacology Research & Perspectives.2021;[Epub]     CrossRef
  • Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment
    Jennifer J. Lin, Catrina M. Loucks, Jessica N. Trueman, Britt I. Drögemöller, Galen E.B. Wright, Eric M. Yoshida, Jo-Ann Ford, Samuel S. Lee, Richard B. Kim, Bandar Al-Judaibi, Ute I. Schwarz, Alnoor Ramji, Edward Tam, Colin J. Ross, Bruce C. Carleton
    Biomedicine & Pharmacotherapy.2021; 143: 112195.     CrossRef
  • Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin
    Chi-Ching Chen, Shui-Yi Tung, Kuo-Liang Wei, Chien-Heng Shen, Te-Sheng Chang, Wei-Ming Chen, Huang-Wei Xu, Chih-Wei Yen, Yi-Hsing Chen, Sheng-Nan Lu, Chao-Hung Hung
    Journal of the Formosan Medical Association.2020; 119(1): 532.     CrossRef
  • Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
    Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2020; 12(11): 3414.     CrossRef
  • Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
    Eun Sun Jang, Kyung-Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook-Hyang Jeong
    Gut and Liver.2020; 14(6): 775.     CrossRef
  • Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium
    Chung-Feng Huang, Etsuko Iio, Dae Won Jun, Eiichi Ogawa, Hidenori Toyoda, Yao-Chun Hsu, Hiroaki Haga, Shinji Iwane, Masaru Enomoto, Dong Hyun Lee, Grace Wong, Chen-Hua Liu, Toshifumi Tada, Wan-Long Chuang, Ramsey Cheung, Jun Hayashi, Cheng-Hao Tseng, Sato
    Hepatology International.2019; 13(5): 587.     CrossRef
  • Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea
    Young-Hwan Ahn, Hyungcheol Park, Myeon Jae Lee, Dong Hyun Kim, Sung Bum Cho, Eunae Cho, Chung Hwan Jun, Sung Kyu Choi
    Gut and Liver.2019; 13(5): 549.     CrossRef
  • Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
    Jong Eun Yeon
    Clinical and Molecular Hepatology.2018; 24(3): 294.     CrossRef
  • Ribavirin/sofosbuvir

    Reactions Weekly.2018; 1727(1): 247.     CrossRef
  • 11,161 View
  • 206 Download
  • 11 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
Byeong Wook Cho, Seok Bae Kim, Il Han Song, Sae Hwan Lee, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Seok Hyun Kim, Byung Seok Lee, Hee Bok Chae
Clin Mol Hepatol 2017;23(1):51-56.
Published online March 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0053
Background/Aims
The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Korean patients with chronic hepatitis C virus (HCV) genotype Ib infection.
Methods
We retrospectively analyzed clinical data from chronic HCV genotype Ib patients treated with DCV+ASV from August 2015 to September 2016 at five hospitals in the Daejeon-Chungcheong area.
Results
A total of 152 patients were examined for resistance associated variants (RAVs). Among them, 15 (9.9%) were positive for Y93 and one (0.7%) was positive for L31. Of 126 patients treated with DCV+ASV, 83 patients completed treatment and 76 patients were included in safety and efficacy analysis. Five (6.6%) were positive for Y93 and 12 (15.8%) exhibited cirrhotic change. DCV+ASV was the first-line treatment for 58 (76.3%) patients. Eleven (14.5%) patients relapsed after previous treatment that included interferon and seven (9.2%) of these patients were found to be intolerant of interferon. Adverse events occurred in 10 (13.2%) patients and two patients stopped the medication because of severe itching and skin rash. SVR12 was 89.5% (68/76) in all patients and 91.5% (65/71) in RAV-negative patients.
Conclusions
DCV+ASV showed good efficacy in patients with HCV Ib infection in Korea. Close monitoring is needed for severe adverse events and treatment failure, which were uncommon.

Citations

Citations to this article as recorded by  Crossref logo
  • The Incidence and Care Cascade of the Hepatitis C Virus in Korea
    Young Eun Chon, Aejeong Jo, Eileen L. Yoon, Jonghyun Lee, Ho Gyun Shin, Min Jung Ko, Dae Won Jun
    Gut and Liver.2023; 17(6): 926.     CrossRef
  • Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment
    Young-Hwan Ahn, Heirim Lee, Ji Eun Han, Hyo Jung Cho, Jae Youn Cheong, Bumhee Park, Soon Sun Kim
    Journal of Liver Cancer.2022; 22(2): 125.     CrossRef
  • Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea
    Jung Hyun Kwon, Sun Hong Yoo, Soon Woo Nam, Hee Yeon Kim, Chang Wook Kim, Chan Ran You, Sang Wook Choi, Se Hyun Cho, Joon‐Yeol Han, Do Seon Song, U Im Chang, Jin Mo Yang, Sung Won Lee, Hae Lim Lee, Nam Ik Han, Seok‐Hwan Kim, Myeong Jun Song, Pil Soo Sung,
    Journal of Medical Virology.2019; 91(6): 1104.     CrossRef
  • Discussion on critical points for a tailored therapy to cure hepatitis C virus infection
    Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
    Clinical and Molecular Hepatology.2019; 25(1): 30.     CrossRef
  • Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
    Byung Seok Lee, Myeong Jun Song, Jung Hyun Kwon, Tae Hee Lee, Ji Woong Jang, Seok Hyun Kim, Sae Hwan Lee, Hong Soo Kim, Ji Hoon Kim, Seok Bae Kim, Soon Young Ko, Do Seon Song
    Gut and Liver.2019; 13(2): 191.     CrossRef
  • Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
    Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak
    The Korean Journal of Internal Medicine.2019; 34(4): 794.     CrossRef
  • Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test
    Eun Sun Jang, Kyung‐Ah Kim, Young Seok Kim, In Hee Kim, Byung Seok Lee, Youn Jae Lee, Woo Jin Chung, Sook‐Hyang Jeong
    Journal of Medical Virology.2019; 91(12): 2158.     CrossRef
  • An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
    Youn Jae Lee, Jeong Heo, Do Young Kim, Woo Jin Chung, Won Young Tak, Yoon Jun Kim, Seung Woon Paik, Eungeol Sim, Susila Kulasingam, Rohit Talwani, Barbara Haber, Peggy Hwang
    Clinical and Molecular Hepatology.2019; 25(4): 400.     CrossRef
  • Systematic review with meta‐analysis: effectiveness and tolerability of interferon‐free direct‐acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia
    F. Ji, B. Wei, Y. H. Yeo, E. Ogawa, B. Zou, C. D. Stave, Z. Li, S. Dang, N. Furusyo, R. C. Cheung, M. H. Nguyen
    Alimentary Pharmacology & Therapeutics.2018; 47(5): 550.     CrossRef
  • Early development of de novo hepatocellular carcinoma after direct‐acting agent therapy: Comparison with pegylated interferon‐based therapy in chronic hepatitis C patients
    S. H. Yoo, J. H. Kwon, S. W. Nam, H. Y. Kim, C. W. Kim, C. R. You, S. W. Choi, S. H. Cho, J.‐Y. Han, D. S. Song, U. I. Chang, J. M. Yang, H. L. Lee, S. W. Lee, N. I. Han, S.‐H. Kim, M. J. Song, S. Hwang, P. S. Sung, J. W. Jang, S. H. Bae, J. Y. Choi, S. K
    Journal of Viral Hepatitis.2018; 25(10): 1189.     CrossRef
  • Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
    Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park
    Gut and Liver.2018; 12(3): 324.     CrossRef
  • Interaction of immunosuppressants with HCV antivirals daclatasvir and asunaprevir: combined effects with mycophenolic acid
    Petra E de Ruiter, Yashna Gadjradj, Robert J de Knegt, Herold J Metselaar, Jan NM Ijzermans, Luc JW van der Laan
    World Journal of Transplantation.2018; 8(5): 156.     CrossRef
  • Asunaprevir/daclatasvir

    Reactions Weekly.2017; 1653(1): 56.     CrossRef
  • Global elimination of hepatitis C virus infection: Progresses and the remaining challenges
    Reza Taherkhani, Fatemeh Farshadpour
    World Journal of Hepatology.2017; 9(33): 1239.     CrossRef
  • 10,974 View
  • 215 Download
  • 12 Web of Science
  • Crossref

Viral hepatitis

Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study
Dae Won Jun, Byung Ik Kim, Yong Kyun Cho, Hong Ju Kim, Young Oh Kwon, Soo Young Park, Sang Young Han, Yang Hyun Baek, Yong Jin Jung, Hwi Young Kim, Won Kim, Jeong Heo, Hyun Young Woo, Seong Gyu Hwang, Kyu Sung Rim, Jong Young Choi, Si Hyun Bae, Young Sang Lee, Young Suck Lim, Jae Youn Cheong, Sung Won Cho, Byung Seok Lee, Seok Hyun Kim, Joo Hyun Sohn, Tae Yeob Kim, Yong Han Paik, Ja Kyung Kim, Kwan Sik Lee
Clin Mol Hepatol 2013;19(2):165-172.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.165
Background/Aims

Carnitine and vitamin complex (Godex®) is widely used in patients with chronic liver disease who show elevated liver enzyme in South Korea. The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients.

Methods

130 treatment-naïve patients with CHB were enrolled from 13 sites. The patients were randomly selected to the entecavir and the complex of entecavir and carnitine. The primary endpoint of the study is ALT normalization level after 12 months.

Results

Among the 130 patients, 119 patients completed the study treatment. The ALT normalization at 3 months was 58.9% for the monotherapy and 95.2% for the combination therapy (P<0.0001). ALT normalization rate at 12 months was 85.7% for the monotherapy and 100% for the combination group (P=0.0019). The rate of less than HBV DNA 300 copies/mL at 12 months was not statistically significant (P=0.5318) 75.9% for the monotherapy, 70.7% for the combination and it was. Quantification of HBsAg level was not different from the monotherapy to combination at 12 months. Changes of ELISPOT value to evaluate the INF-γ secretion by HBsAg showed the increasing trend of combination therapy compare to mono-treatment.

Conclusions

ALT normalization rate was higher in carnitine complex combination group than entecavir group in CHB. Combination group was faster than entecavir mono-treatment group on ALT normalization rate. HBV DNA normalization rate and the serum HBV-DNA level were not changed by carnitine complex treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Developments in small molecule antiviral drugs against hepatitis B and C viruses: FDA approved therapies and new drugs in clinical trials
    Palak K. Parikh, Nisha H. Parikh, Mahalakshmi B, Ketan M. Ranch, Sai H.S. Boddu, Jayachandra Babu R, Amit K. Tiwari
    Arabian Journal of Chemistry.2023; 16(8): 105013.     CrossRef
  • Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
    Hyung Joon Yim, Won Kim, Sang Hoon Ahn, Young Kul Jung, Soon Ho Um, Joo Hyun Sohn, Jae Young Jang, Dong Joon Kim, Eun‐Sook Park, So‐Young Jin, Kyun‐Hwan Kim
    Journal of Gastroenterology and Hepatology.2022; 37(2): 378.     CrossRef
  • Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center–Related Immune Cells
    Shuqin Gu, Weibin Wang, Guofu Ye, Chengcong Chen, Yang Zhou, Ling Guo, Shihong Zhong, Xiaoyi Li, Xin Fu, Chunhua Wen, Libo Tang, Jian Sun, Jinlin Hou, Yongyin Li
    The Journal of Infectious Diseases.2022; 225(11): 1955.     CrossRef
  • Effect of L-carnitine on quality of life in covert hepatic encephalopathy: a randomized, double-blind, placebo-controlled study
    Eileen L. Yoon, Sang Bong Ahn, Dae Won Jun, Yong Kyun Cho, Do Seon Song, Jae Yoon Jeong, Hee Yeon Kim, Young Kul Jung, Myeong Jun Song, Sung Eun Kim, Hyoung Su Kim, Soung Won Jeong, Sang Gyune Kim, Tae Hee Lee
    The Korean Journal of Internal Medicine.2022; 37(4): 757.     CrossRef
  • Impact of l-Carnitine Supplementation on Liver Enzyme Normalization in Patients with Chronic Liver Disease: A Meta-Analysis of Randomized Trials
    Hyunwoo Oh, Chan Hyuk Park, Dae Won Jun
    Journal of Personalized Medicine.2022; 12(7): 1053.     CrossRef
  • Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
    Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
    Clinical and Molecular Hepatology.2022; 28(3): 425.     CrossRef
  • Prolonged Use of Carnitine-Orotate Complex (Godex®) Is Associated with Improved Mortality: A Nationwide Cohort Study
    Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park
    Journal of Personalized Medicine.2022; 12(12): 1970.     CrossRef
  • Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update
    Na Li, Hui Zhao
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection
    Shuqin Gu, Xin Fu, Guofu Ye, Chengcong Chen, Xiaoyi Li, Shihong Zhong, Libo Tang, Haitao Chen, Deke Jiang, Jinlin Hou, Yongyin Li
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway
    Jung-Hee Hong, Moon-Kyu Lee
    Diabetes & Metabolism Journal.2021; 45(6): 933.     CrossRef
  • Does l-carnitine supplementation affect serum levels of enzymes mainly produced by liver? A systematic review and meta-analysis of randomized controlled clinical trials
    Farzaneh Pirmadah, Nahid Ramezani-Jolfaie, Mohammad Mohammadi, Nasir Talenezhad, Cain C. T. Clark, Amin Salehi-Abargouei
    European Journal of Nutrition.2020; 59(5): 1767.     CrossRef
  • The protective role of l-carnitine against 1st- and 2nd-generation antihistamine-induced liver injury in mice
    Rania A. Abdel-Emam, Esraa A. Ahmed, Marwa F. Ali
    Comparative Clinical Pathology.2020; 29(1): 213.     CrossRef
  • Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B
    Yeon Woo Jung, Moonhyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Journal of Korean Medical Science.2020;[Epub]     CrossRef
  • Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials
    Esmaeil Yousefi Rad, Elham Eslampour, Ebrahim Falahi, Mahnaz Mardani, Azita Hekmatdoost, Omid Asbaghi, Somayeh Saboori
    Indian Journal of Gastroenterology.2019; 38(6): 470.     CrossRef
  • L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
    Masatsugu Ohara, Koji Ogawa, Goki Suda, Megumi Kimura, Osamu Maehara, Tomoe Shimazaki, Kazuharu Suzuki, Akihisa Nakamura, Machiko Umemura, Takaaki Izumi, Naoki Kawagishi, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, Shunsuke Ohnishi,
    Hepatology Communications.2018; 2(8): 910.     CrossRef
  • Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature
    Rachael R. Schulte, Manasi V. Madiwale, Allyson Flower, Jessica Hochberg, Michael J. Burke, Jennifer L. McNeer, Adam DuVall, Archie Bleyer
    Leukemia & Lymphoma.2018; 59(10): 2360.     CrossRef
  • Anti-adipogenic and antiviral effects ofl-carnitine on hepatitis C virus infection
    Yoko Tsukuda, Goki Suda, Seiji Tsunematsu, Jun Ito, Fumiyuki Sato, Katsumi Terashita, Masato Nakai, Takuya Sho, Osamu Maehara, Tomoe Shimazaki, Megumi Kimura, Kenichi Morikawa, Mitsuteru Natsuizaka, Koji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Naoya Sakamo
    Journal of Medical Virology.2017; 89(5): 857.     CrossRef
  • Glycyrrhetic acid, but not glycyrrhizic acid, strengthened entecavir activity by promoting its subcellular distribution in the liver via efflux inhibition
    Qianying Chen, Hongzhu Chen, Wenjie Wang, Jiali Liu, Wenyue Liu, Ping Ni, Guowei Sang, Guangji Wang, Fang Zhou, Jingwei Zhang
    European Journal of Pharmaceutical Sciences.2017; 106: 313.     CrossRef
  • A Case of Therapeutic Laser for Suggested Drug Induced Liver Injury Patient during Treatment of Korean Medicine
    Kyeong-Tae Lim, Byung-Cheul Shin, Eui-Hyoung Hwang, In Heo, Byung-Jun Kim, Kwang-Ho Heo
    Journal of Korean Medicine Rehabilitation.2016; 26(3): 183.     CrossRef
  • Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition
    Zhongqi Dong, Sean Ekins, James E. Polli
    European Journal of Pharmaceutical Sciences.2015; 66: 1.     CrossRef
  • Comparison on the Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid in Patients with Abnormal Alanine Aminotransferase: Multicenter, Double-blinded, Randomized, Active-controlled Clinical Trial
    Sae Hwan Lee, Gab Jin Cheon, Hong Soo Kim, Young Don Kim, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
    The Korean Journal of Gastroenterology.2014; 64(1): 31.     CrossRef
  • 13,832 View
  • 177 Download
  • Crossref
The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care
Hyuk Soo Eun, Min Jung Kim, Hye Jin Kim, Kwang Hun Ko, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee
Korean J Hepatol 2011;17(3):189-198.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.189
Background/Aims

This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).

Methods

From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.

Results

Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.

Conclusions

We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology
    Senarath Pathiranage Nimasha Ekanayaka, Nathasha Luke, Suchintha Bandara Thilakarathne, Anuradha Dassanayake, Mahiman Bhaagya Gunetilleke, Madunil A. Niriella, Rohan Chaminda Siriwardana
    Indian Journal of Gastroenterology.2024; 43(6): 1176.     CrossRef
  • Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma
    Kuan-Wei Huang, Yu-Tsung Lai, Guann-Jen Chern, Shao-Feng Huang, Chia-Lung Tsai, Yun-Chieh Sung, Cheng-Chin Chiang, Pi-Bei Hwang, Ting-Lun Ho, Rui-Lin Huang, Ting-Yun Shiue, Yunching Chen, Sheng-Kai Wang
    Biomacromolecules.2018; 19(6): 2330.     CrossRef
  • Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2016; 22(30): 6851.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives
    Jan Erik Slotta
    World Journal of Hepatology.2015; 7(9): 1168.     CrossRef
  • Considerations for Radiation Therapy in Hepatocellular Carcinoma: The Radiation Oncologists' Perspective
    Jeong Il Yu, Hee Chul Park
    Digestive Diseases.2014; 32(6): 755.     CrossRef
  • 9,527 View
  • 73 Download
  • Crossref
A study of the awareness of chronic liver diseases among Korean adults
Dae Won Jun, Yong Kyun Cho, Joo Hyun Sohn, Chang Hyeong Lee, Seok Hyun Kim, Jong Ryul Eun
Korean J Hepatol 2011;17(2):99-105.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.99
Background/Aims

Chronic liver disease is closely associated with lifestyle, and public enlightenment of the lifestyle factors is important in reducing prevalence of chronic liver disease. The KASL (Korean Association for the Study of the Liver) conducted a survey of basic information and epidemiological data regarding chronic liver diseases.

Methods

A survey of chronic liver disease involving a total of 2,794 respondents was conducted. The respondents included patients and their guardians, visitors for health check-ups, and online pollees who completed a questionnaire on the awareness of fatty liver or chronic liver disease.

Results

Of the entire cohort, 854 (39.7%) said they have had or still have fatty liver or an elevated transaminase level (>40 IU/L), but only 23.4% of the respondents had visited a hospital. It was found that 35% of healthy subjects and 45% of patients and their guardians misunderstood hepatitis B as the hereditary disesase. Furthermore, 26% of the subjects responded that patients with inactive hepatitis B do not require regular follow-up. While 17.9% answered that it is not too late to test for liver cancer when symptoms arise, 38.8% believed that liver transplant in liver cancer patients has a low success rate and is thus not recommended.

Conclusions

Despite the inundation of information and widespread media advertising, the awareness of chronic liver disease is unsatisfactory among Korean adults. Systematic nationwide studies are needed to obtain data and information regarding the prevalence of chronic liver disease and patterns of use of the health-care system.

Citations

Citations to this article as recorded by  Crossref logo
  • Understanding Hepatitis B Knowledge, Attitudes, and Stigma in the Korean Community in Australia
    Youngnam Baek, Robyn Horwitz, Loren Brener, Sylvester Okeke, Tim Broady, Carla Treloar, Elena Cama
    Journal of Racial and Ethnic Health Disparities.2025;[Epub]     CrossRef
  • Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
    Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
    Heliyon.2024; 10(22): e40217.     CrossRef
  • Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
    Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, Pietro Lampertico, Maria Buti, Claude B. Sirlin, Mindie H. Nguyen, Rohit Loomba
    Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 797.     CrossRef
  • Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study
    Mei Hsuan Lee, Sang Hoon Ahn, Henry L. Y. Chan, Asad Choudhry, Rino Alvani Gani, Rosmawati Mohamed, Janus P. Ong, Akash Shukla, Chee Kiat Tan, Tawesak Tanwandee, Pham Thi Thu Thuy, Boon Leong Neo, Venus Tsang, Jin Youn, Shikha Singh
    Journal of Viral Hepatitis.2022; 29(2): 156.     CrossRef
  • The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
    Naim Alkhouri, Ashraf Almomani, Phuc Le, Julia Y. Payne, Imad Asaad, Celine Sakkal, Miriam Vos, Mazen Noureddin, Prabhat Kumar
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study
    Ammal M. Metwally, Dalia M. Elmosalami, Hazem Elhariri, Lobna A. El Etreby, Ahmed Aboulghate, Marwa M. El-Sonbaty, Amira Mohsen, Rehan M. Saleh, Ghada A. Abdel-Latif, Sahar Samy, Sherif E. El Deeb, Asmaa M. Fathy, Mohab M. Salah, Mohamed A. Abdel Mawla, H
    PLOS ONE.2021; 16(2): e0242257.     CrossRef
  • Self-testing for liver disease – response to an online liver test questionnaire
    Achim Kautz, Rebecca Dorner, Christoph Antoni, Matthias Ebert, Andreas Teufel
    Scandinavian Journal of Gastroenterology.2020; 55(1): 67.     CrossRef
  • Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals
    Saikat Banerjee, Sampada Kumar Dash
    Health Marketing Quarterly.2018; 35(2): 134.     CrossRef
  • Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
    Ho Hyun Nam, Dae Won Jun, Kiseok Jang, Waqar Khalid Saeed, Jai Sun Lee, Hyeon Tae Kang, Yeon Ji Chae
    Oncotarget.2017; 8(58): 97965.     CrossRef
  • Usefulness of Ultrasonographic Scoring System in Diagnosis of Alcoholic Cirrhosis
    Kyoung Min Moon, Soon Koo Baik
    Clinical Ultrasound.2016; 1(2): 92.     CrossRef
  • Hepatoprotective effects ofRubus coreanusmiquel concentrates on liver injuries induced by carbon tetrachloride in rats
    Hyun-Jung Chae, Jung-Eun Yim, Kyung-Ah Kim, Jong-Hee Chyun
    Nutrition Research and Practice.2014; 8(1): 40.     CrossRef
  • Efficacy and Safety of Human Placental Extract for Alcoholic and Nonalcoholic Steatohepatitis: An Open-Label, Randomized, Comparative Study
    Jin Young Choi, Kyeheui Lee, Seung Min Lee, Sun Hong Yoo, Seong Gyu Hwang, Jong Young Choi, Sang Wook Lee, Jae Seok Hwang, Kyoung Kon Kim, Hee Cheol Kang, Gab Jin Cheon, Young Min Park
    Biological and Pharmaceutical Bulletin.2014; 37(12): 1853.     CrossRef
  • Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis
    Kyoung Min Moon, Gaeun Kim, Soon Koo Baik, Eunhee Choi, Moon Young Kim, Hyoun A Kim, Mee Yon Cho, Seung Yong Shin, Jung Min Kim, Hong Jun Park, Sang Ok Kwon, Young Woo Eom
    Clinical and Molecular Hepatology.2013; 19(4): 389.     CrossRef
  • Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
    John FP Bridges, Liming Dong, Gisselle Gallego, Barri M Blauvelt, Susan M Joy, Timothy M Pawlik
    BMC Health Services Research.2012;[Epub]     CrossRef
  • 10,806 View
  • 56 Download
  • Crossref
Case Report
A case of concomitant Gilbert's syndrome and hereditary spherocytosis
Hee Jung Lee, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Jae Kyu Sung, Byung Seok Lee, Hyun Yong Jeong, Heon Young Lee, Young Jae Eu
Korean J Hepatol 2010;16(3):321-324.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.321

We describe moderate hyperbilirubinemia in a 28-year-old man who suffered from gallstones and splenomegaly, with combined disorders of hereditary spherocytosis (HS) and Gilbert's syndrome (GS). Since it is difficult to diagnose HS in the absence of signs of anemia, we evaluated both the genetic mutation in the UGT1A1 gene and abnormalities in the erythrocyte membrane protein; the former was heterozygous for a UGT1A1 allele with three mutations and the latter was partially deficient in ankyrin expression. This is the first report of the concomitance of HS and GS with three heterozygous mutations [T-3279G, A (TA)7TAA, and G211A] in the UGT1A1 gene.

Citations

Citations to this article as recorded by  Crossref logo
  • Gilbert syndrome in patients with inherited hemolytic anemia modifies the clinical phenotype
    Anika Agrawal, Jagdish Chandra
    Pediatric Hematology Oncology Journal.2024; 9(2): 62.     CrossRef
  • A Case of Adult Hereditary Spherocytosis Concomitant with Gilbert Syndrome Caused by Mutations in SPTB and UGT1A1
    Yang Gou, Ping Wang, Wucheng Yang, Yimei Feng, Xiangui Peng, Hong Liu, Shuiqing Liu, Xi Zhang
    Journal of Inflammation Research.2024; Volume 17: 5977.     CrossRef
  • Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report
    Guzailinuer Wufuer, Kaisaer Wufuer, Tu Ba, Tao Cui, Ling Tao, Ling Fu, Ming Mao, Ming-Hui Duan
    World Journal of Clinical Cases.2022; 10(13): 4161.     CrossRef
  • Gilbert's Syndrome, Bilirubin Level and UGT1A1∗28 Genotype in Men of North-West Region of Russia
    Andrei Ivanov, Elena Semenova
    Journal of Clinical and Experimental Hepatology.2021; 11(6): 691.     CrossRef
  • Gilbert’s syndrome coexisting with hereditary spherocytosis might not be rare: Six case reports
    Ling-Ling Kang, Ze-Lin Liu, Hou-De Zhang
    World Journal of Clinical Cases.2020; 8(10): 2001.     CrossRef
  • Molecular Genetic Mechanisms of Hereditary Spherocytosis: Current Perspectives
    Ben-Jin He, Lin Liao, Zeng-Fu Deng, Yi-Feng Tao, Yu-Chan Xu, Fa-Quan Lin
    Acta Haematologica.2018; 139(1): 60.     CrossRef
  • Gilbert Syndrome with Concomitant Hereditary Spherocytosis Presenting with Moderate Unconjugated Hyperbilirubinemia
    Mitsuhiko Aiso, Minami Yagi, Atsushi Tanaka, Kotaro Miura, Ryo Miura, Toshihiko Arizumi, Yoriyuki Takamori, Sayuri Nakahara, Yoshihiro Maruo, Hajime Takikawa
    Internal Medicine.2017; 56(6): 661.     CrossRef
  • Scoliosis in a Patient With Gilbert Syndrome
    Zheng Li, Jianxiong Shen, Jinqian Liang
    Medicine.2015; 94(47): e2147.     CrossRef
  • Coexistence of Gilbert Syndrome and Hereditary Spherocytosis in a Child Presenting with Extreme Jaundice
    Jae Hee Lee, Kyung Rye Moon
    Pediatric Gastroenterology, Hepatology & Nutrition.2014; 17(4): 266.     CrossRef
  • A Case of Hereditary Spherocytosis Coexisting with Gilbert's Syndrome
    Min-Jae Lee, Yoon Hwan Chang, Seung-Hwa Kang, Se-Kwon Mun, Heyjin Kim, Chul Ju Han, Jin Kim, Hye Jin Kang
    The Korean Journal of Gastroenterology.2013; 61(3): 166.     CrossRef
  • Severe unconjugated hyperbilirubinaemia: one and one makes three?
    Kushal Naha, Sowjanya Dasari, G Vivek, Manjunath Hande, Vasudev Acharya
    BMJ Case Reports.2013; 2013: bcr2013009962.     CrossRef
  • 9,919 View
  • 68 Download
  • Crossref